← All candidates
Eight insider buys in the last year — $75.06M in all.
20 filings on record.
GENBGenerate Biomedicines, Inc.
—
$14.49
+1.19% · Sep 15
Eight insider buys in the last year — $75.06M in all.
Nothing in the last fortnight.
Price · 1Y · daily● 8 buys
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
10% owner
Afeyan Noubar
Bought $25.00M on Mar 2 — 1,562,500 sh @ $16.00, held indirect, 100% of their stake.
1 of 1 position beat the S&P
Director
Mendillo Jane L
Bought $24.0K on Mar 2 — 1,500 sh @ $16.00, held direct, 100% of their stake.
1 of 1 position beat the S&P
President & CFO
Silvers Jason
Bought $16.0K on Mar 2 — 1,000 sh @ $16.00, held indirect, 100% of their stake.
1 of 1 position beat the S&P
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
15 more transactions on Pro →Context
Wall St
$25.40 avg target
+75.3% vs today · 5 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
0 of 1 quarters beat
Q1 '26−$1.07 act−$0.56
Coverage
A Look At Generate Biomedicines (GENB) Valuation As Shares Soften After Recent GainsSimply Wall St. · 06-01H.C. Wainwright Initiates Coverage of Generate Biomedicines (GENB) With a Buy RatingInsider Monkey · 04-20Generate Biomedicines (GENB) Valuation Check After Recent Share Price WeaknessSimply Wall St. · 03-08A New $21 Million Position Signals Confidence in This Post-IPO Drug DeveloperMotley Fool · 05-31
The file stays open
20 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice